In a patient with chronic heart failure with reduced EF, which SGLT2 inhibitor has demonstrated reduction in both cardiovascular death/hospitalisation for HF and progression of CKD, regardless of diabetes status?

• A Canagliflozin
• B Ertugliflozin
• C Ipragliflozin
• D Dapagliflozin ✓

Explanation

Dapagliflozin (DAPA-HF trial) and empagliflozin (EMPEROR-Reduced) demonstrated significant reduction in cardiovascular death and hospitalisation for HF with reduced EF, regardless of diabetes status. Dapagliflozin additionally showed renoprotective benefits in the DAPA-CKD trial. Canagliflozin was shown in CREDENCE to reduce CKD progression in diabetic nephropathy but its HFrEF mortality data is less robust; ertugliflozin and ipragliflozin lack equivalent outcome data.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.